(Q35111841)

6 August 2017

1 reference

title

Abandoned therapies and unpublished trials in rheumatoid arthritis (English)

1 reference

6 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

26 December 2023

author name string

Edward C. Keystone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12707578

26 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12707578

26 December 2023

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://journals.lww.com/00002281-200305000-00012

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Current Opinion in Rheumatology

26 December 2023

published in

1 reference

6 August 2017

volume

15

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

253-258

1 reference

Biologic agents in the treatment of rheumatoid arthritis

6 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Potential biologic agents for treating rheumatoid arthritis

26 December 2023

2

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis

26 December 2023

3

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Biological therapies: a novel approach to the treatment of autoimmune disease

26 December 2023

4

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Immunopathogenesis and immunotherapy in rheumatoid arthritis: an area in transition.

26 December 2023

5

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

26 December 2023

6

23

1338

Kavanaugh

1996

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1

26 December 2023

7

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

26 December 2023

9

29

447

2002

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts.

26 December 2023

10

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.

26 December 2023

12

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

A randomized, double‐blind, placebo‐controlled study of cd4 monoclonal antibody therapy in early rheumatoid arthritis

26 December 2023

13

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience

26 December 2023

14

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

The New England Journal of Medicine

26 December 2023

15

322

1651

Moreland

1999

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis

26 December 2023

16

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Synovial tissue response to treatment with Campath-1H

26 December 2023

17

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens

26 December 2023

18

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

26 December 2023

21

29

220

Mason

2002

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens

26 December 2023

22

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Humanised monoclonal antibody therapy for rheumatoid arthritis

26 December 2023

23

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis

26 December 2023

24

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

26 December 2023

25

24

1031

Schnitzer

1997

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group

26 December 2023

26

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

26 December 2023

27

39

314A

Sewell

1991

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

26 December 2023

28

27

1855

St Clair

2000

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

26 December 2023

29

23

1353

Moreland

1996

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides

26 December 2023

30

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial

26 December 2023

32

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Induction of tolerance with intranasal administration of human cartilage gp-39 in DBA/1 mice: amelioration of clinical, histologic, and radiologic signs of type II collagen-induced arthritis

26 December 2023

33

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis.

26 December 2023

34

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis

26 December 2023

42

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

26 December 2023

43

20

1867

Cannon

1993

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study

26 December 2023

46

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Interferon in chronic polyarthritis. Positive effect in clinical evaluation

26 December 2023

47

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

26 December 2023

Journal of Immunology

48

152

2060

Seitz

1994

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

A multicenter study of hospitalization in rheumatoid arthritis. Frequency, medical-surgical admissions, and charges

26 December 2023

50

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis

26 December 2023

51

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat

26 December 2023

52

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo

26 December 2023

53

1 reference

https://api.crossref.org/works/10.1097/00002281-200305000-00012

26 December 2023

Identifiers

1 reference

6 August 2017

1 reference